Literature DB >> 23857961

Quality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Societe Francaise d'Oncologie Gynecologique, SFOG).

D Querleu1, I Ray-Coquard, J M Classe, J S Aucouturier, F Bonnet, P Bonnier, E Darai, M Devouassoux, L Gladieff, O Glehen, C Haie-Meder, F Joly, F Lécuru, J P Lefranc, C Lhommé, P Morice, A Salengro, E Stoeckle, S Taieb, Z X Zeng, E Leblanc.   

Abstract

BACKGROUND: Based on registries, the European experience has been that <50% of patients are treated according to protocols and/or benefit from the minimum required surgery for ovarian cancer. The French Cancer Plan 2009-2013 considers the definition of qualitative indicators in ovarian cancer surgery in France. This endeavour was undertaken by the French Society of Gynaecologic Oncology (SFOG) in partnership with the French National College of Obstetricians and Gynecologists and all concerned learned societies in a multidisciplinary mindset.
METHODS: The quality indicators for the initial management of patients with ovarian cancer were based on the standards of practice determined from scientific evidence or expert consensus.
RESULTS: The indicators were divided into structural indicators, including material (equipment), human (number and qualification of staff), and organizational resources, process indicators, and outcome indicators.
CONCLUSIONS: The enforcement of a quality assurance programme in any country would undoubtedly promote improvement in the quality of care for ovarian cancer patients and would result in a dramatic positive impact on their survival. Such a policy is not only beneficial to the patient, but is also profitable for the healthcare system.

Entities:  

Keywords:  gynaecologic oncology; ovarian cancer; quality assurance; surgical oncology

Mesh:

Year:  2013        PMID: 23857961     DOI: 10.1093/annonc/mdt237

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

Review 1.  Novel Surgical Strategies in the Treatment of Gynecological Malignancies.

Authors:  Martina Aida Angeles; Carlos Martínez-Gómez; Federico Migliorelli; Marie Voglimacci; Justine Figurelli; Stephanie Motton; Yann Tanguy Le Gac; Gwénaël Ferron; Alejandra Martinez
Journal:  Curr Treat Options Oncol       Date:  2018-11-09

2.  Impact of hospital and surgeon case volume on morbidity in colorectal endometriosis management: a plea to define criteria for expert centers.

Authors:  Sofiane Bendifallah; Horace Roman; Chrystel Rubod; Pierre Leguevaque; Antoine Watrelot; Nicolas Bourdel; Marcos Ballester; Emile Darai
Journal:  Surg Endosc       Date:  2017-10-24       Impact factor: 4.584

3.  Acceptability of quality indicators for the management of endometrial, cervical and ovarian cancer: results of an online survey.

Authors:  Annemie Luyckx; Leen Wyckmans; Anne-Sophie Bonte; Xuan Bich Trinh; Peter A van Dam
Journal:  BMC Womens Health       Date:  2020-07-23       Impact factor: 2.809

4.  Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation.

Authors:  Kahren M White; Holly Seale; Reema Harrison
Journal:  BMC Public Health       Date:  2019-03-12       Impact factor: 3.295

5.  Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival.

Authors:  Yohann Dabi; Cyrille Huchon; Lobna Ouldamer; Sofiane Bendifallah; Pierre Collinet; Alexandre Bricou; Emile Daraï; Marcos Ballester; Vincent Lavoue; Bassam Haddad; Cyril Touboul
Journal:  J Transl Med       Date:  2020-03-23       Impact factor: 5.531

6.  Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC Study.

Authors:  Martinez Alejandra; Witold Gertych; Christophe Pomel; Gwenael Ferron; Amelie Lusque; Martina Aida Angeles; Eric Lambaudie; Roman Rouzier; Naoual Bakrin; Francois Golfier; Olivier Glehen; Michel Canis; Nicolas Bourdel; Nicolas Pouget; Pierre-Emmanuel Colombo; Frédéric Guyon; Jacques Meurette; Denis Querleu
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.